News: The Latest
Press Releases
Bicara Therapeutics Expands Management Team with the Appointment of David Raben, M.D., as Chief Medical Officer
Contact Information
GENERAL
BUSINESS DEVELOPMENT
MEDIA
Dan Budwick
1AB
dan@1abmedia.com
INVESTORS
Hannah Deresiewicz
Stern Investor Relations, Inc.
Hannah.Deresiewicz@sternir.com
Presentations & Publications
Webinar: ASCO 2023 Update: BCA101 With Pembrolizumab Dose Expansion Results in Patients With R/M HNSCC
Presented by Bicara Therapeutics
June 2023
Publication: BCA101, a novel tumor-targeted bifunctional fusion antibody simultaneously inhibiting EGFR and TGF-β signaling with potential for durable tumor growth inhibition
Cancer Research
April 2023
Poster Presentation: BCA101, a novel tumor-targeted bifunctional fusion antibody simultaneously inhibiting EGFR and TGF-β signaling with potential for durable tumor growth inhibition
American Association for Cancer Research 2023 Annual Meeting
April 2023
Poster Presentation: Preliminary immune correlatives from BCA101 trial show favorable modulation of tumor immune microenvironment
American Association for Cancer Research 2023 Annual Meeting
April 2023
Poster Presentation: An improved trispecific antibody (TsAb) platform for optimally engaging T cells for the treatment of solid tumor malignancies
American Association for Cancer Research 2023 Annual Meeting
April 2023
Poster Presentation: A novel bispecific BCA356 targeting tumor antigen CAIX conjugated to an attenuated IL-12 demonstrates pre-clinical efficacy with potential for limited systemic toxicity
Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
November 2022
Webinar: Clinical Update on BCA101: Overview and Discussion of Newly Presented Data
Presented by Bicara Therapeutics
September 2022
Poster Presentation: A Phase I trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid cancers
American Society of Clinical Oncology
June 2022
Poster Presentation: Development of BCA101, a bifunctional antibody capable of simultaneously disabling EGFR and TGF-β Signaling, as a novel single-agent immunotherapy
Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting
November 2021
Digital Presentation: First-in-human Phase I study of the bifunctional EGFR/TGFβ fusion protein BCA101 in patients with EGFR-driven advanced solid cancers
American Society of Clinical Oncology
June 2021